Literature DB >> 29622942

Pharmacological Agents Utilized in Patients With Type-2 Diabetes: Beyond Lowering A1c.

Joanna W Chung, Melody L Hartzler, Ashley Smith, Jessica Hatton, Kristi Kelley.   

Abstract

Staying up to date with evolving pharmacotherapies is important to providing optimal therapies to patients. The authors present available evidence to support the role of novel and existing agents in treating type-2 diabetes.

Entities:  

Year:  2018        PMID： 29622942      PMCID： PMC5871242     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  64 in total

1.  Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis.

Authors:  Floris A van de Laar; Peter L Lucassen; Reinier P Akkermans; Eloy H van de Lisdonk; Guy E Rutten; Chris van Weel
Journal:  Diabetes Care       Date:  2005-01       Impact factor: 19.112

Review 2.  Insulin resistance, diabetes, and the adipocyte.

Authors:  Mark W Stolar
Journal:  Am J Health Syst Pharm       Date:  2002-12-01       Impact factor: 2.637

3.  Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Rury R Holman; M Angelyn Bethel; Robert J Mentz; Vivian P Thompson; Yuliya Lokhnygina; John B Buse; Juliana C Chan; Jasmine Choi; Stephanie M Gustavson; Nayyar Iqbal; Aldo P Maggioni; Steven P Marso; Peter Öhman; Neha J Pagidipati; Neil Poulter; Ambady Ramachandran; Bernard Zinman; Adrian F Hernandez
Journal:  N Engl J Med       Date:  2017-09-14       Impact factor: 91.245

4.  Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews
Journal:  Diabetes Care       Date:  2015-01       Impact factor: 19.112

5.  Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years.

Authors:  Xiang-Yang Liu; Ning Zhang; Rui Chen; Jia-Guo Zhao; Pei Yu
Journal:  J Diabetes Complications       Date:  2015-07-21       Impact factor: 2.852

6.  Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies.

Authors:  Helle Linnebjerg; Eric Chen Quin Lam; Mary E Seger; David Coutant; Laiyi Chua; Chew Lan Chong; Maria M Ferreira; Danny Soon; Xin Zhang
Journal:  Diabetes Care       Date:  2015-08-25       Impact factor: 19.112

7.  Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy.

Authors:  Aylin A Riedel; Herbert Heien; Jenifer Wogen; Craig A Plauschinat
Journal:  Pharmacotherapy       Date:  2007-08       Impact factor: 4.705

8.  Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors.

Authors:  Baptist Gallwitz
Journal:  Ther Adv Endocrinol Metab       Date:  2013-06       Impact factor: 3.565

9.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse
Journal:  N Engl J Med       Date:  2016-06-13       Impact factor: 176.079

10.  Rationale and design of the randomised controlled trial to assess the impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes (the LYDIA study).

Authors:  Z Z Htike; T Yates; E M Brady; D Webb; L J Gray; D Swarbrick; G P McCann; K Khunti; M J Davies
Journal:  Cardiovasc Diabetol       Date:  2016-07-21       Impact factor: 9.951
View more
  1 in total

Review 1.  The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development.

Authors:  Fan Hong; Pengfei Xu; Yonggong Zhai
Journal:  Int J Mol Sci       Date:  2018-07-27       Impact factor: 5.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.